3.7. Exploratory Outcome Measures
toxicity
The descriptive results of the key exploratory outcome measures are described here with the remainder described in the The median (Q1–Q3) of the Global Quality of Life/Global Health Status score was lower for the IG than for the CG at T0 (IG: 66.67 (58.33–83.33) vs. CG: 83.33 (50.00–91.67)). However, at T3, the IG had the same median score as they had reported at T0 (66.67 (50.00–83.33)), while the CG reported a lower score compared to their T0 score (66.67 (58.33–83.33)).A proportion of subjects, in both groups, experienced at least one treatment dose reduction of >10% (IG: 26.9% vs. CG 36.4%). Reported dose reductions were mainly due to haematological toxicity or non-treatment-related reasons. Similarly, a proportion of subjects in both groups experienced at least one treatment delay, interruption, or premature stop (IG: 38.5%, CG: 27.3%).Two subjects in the IG consumed an additional ONS for, respectively, 3 and 8 intervention days. In the CG, only one subject received a prescription of ONS (Fortimel